- Home
- SID vs DYN Comparison
SID vs DYN Comparison
Compare SID & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SID
- DYN
- Stock Information
- Founded
- SID 1941
- DYN 1984
- Country
- SID Brazil
- DYN United States
- Employees
- SID N/A
- DYN N/A
- Industry
- SID Steel/Iron Ore
- DYN Medicinal Chemicals and Botanical Products
- Sector
- SID Industrials
- DYN Health Care
- Exchange
- SID Nasdaq
- DYN Nasdaq
- Market Cap
- SID 2.3B
- DYN 2.6B
- IPO Year
- SID 1997
- DYN 2020
- Fundamental
- Price
- SID $1.54
- DYN $23.99
- Analyst Decision
- SID Sell
- DYN Strong Buy
- Analyst Count
- SID 2
- DYN 11
- Target Price
- SID $2.95
- DYN $51.18
- AVG Volume (30 Days)
- SID 2.7M
- DYN 891.4K
- Earning Date
- SID 11-12-2024
- DYN 11-12-2024
- Dividend Yield
- SID 19.03%
- DYN N/A
- EPS Growth
- SID N/A
- DYN N/A
- EPS
- SID N/A
- DYN N/A
- Revenue
- SID $8,019,254,042.00
- DYN N/A
- Revenue This Year
- SID N/A
- DYN N/A
- Revenue Next Year
- SID $1.48
- DYN N/A
- P/E Ratio
- SID N/A
- DYN N/A
- Revenue Growth
- SID N/A
- DYN N/A
- 52 Week Low
- SID $1.50
- DYN $12.06
- 52 Week High
- SID $4.03
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- SID 26.68
- DYN 32.86
- Support Level
- SID $1.50
- DYN $25.08
- Resistance Level
- SID $1.97
- DYN $26.69
- Average True Range (ATR)
- SID 0.08
- DYN 1.48
- MACD
- SID -0.03
- DYN -0.36
- Stochastic Oscillator
- SID 7.29
- DYN 5.29
About SID Companhia Siderurgica Nacional S.A.
Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.